Literature DB >> 9585350

Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.

M G Murer1, G Dziewczapolski, L B Menalled, M C García, Y Agid, O Gershanik, R Raisman-Vozari.   

Abstract

Orally administered levodopa remains the most effective symptomatic treatment for Parkinson's disease (PD). The introduction of levodopa therapy is often delayed, however, because of the fear that it might be toxic for the remaining dopaminergic neurons and, thus, accelerate the deterioration of patients. However, in vivo evidence of levodopa toxicity is scarce. We have evaluated the effects of a 6-month oral levodopa treatment on several dopaminergic markers, in rats with moderate or severe 6-hydroxydopamine-induced lesions of mesencephalic dopamine neurons and sham-lesioned animals. Counts of tyrosine hydroxylase (TH)-immunoreactive neurons in the substantia nigra and ventral tegmental area showed no significant difference between levodopa-treated and vehicle-treated rats. In addition, for rats of the sham-lesioned and severely lesioned groups, immunoradiolabeling for TH, the dopamine transporter (DAT), and the vesicular monoamine transporter (VMAT2) at the striatal level was not significantly different between rats treated with levodopa or vehicle. It was unexpected that quantification of immunoautoradiograms showed a partial recovery of all three dopaminergic markers (TH, DAT, and VMAT2) in the denervated territories of the striatum of moderately lesioned rats receiving levodopa. Furthermore, the density of TH-positive fibers observed in moderately lesioned rats was higher in those treated chronically with levodopa than in those receiving vehicle. Last, that chronic levodopa administration reversed the up-regulation of D2 dopamine receptors seen in severely lesioned rats provided evidence that levodopa reached a biologically active concentration at the basal ganglia. Our results demonstrate that a pharmacologically effective 6-month oral levodopa treatment is not toxic for remaining dopamine neurons in a rat model of PD but instead promotes the recovery of striatal innervation in rats with partial lesions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9585350     DOI: 10.1002/ana.410430504

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  37 in total

1.  Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite.

Authors:  Lydia M Mexas; Virginia R Florang; Jonathan A Doorn
Journal:  Neurotoxicology       Date:  2011-04-14       Impact factor: 4.294

2.  Parkinson disease: the controversy of levodopa toxicity in Parkinson disease.

Authors:  Theresa A Zesiewicz
Journal:  Nat Rev Neurol       Date:  2011-12-26       Impact factor: 42.937

Review 3.  Positron emission tomography and single-photon emission computed tomography in central nervous system drug development.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2005-04

4.  Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.

Authors:  Nicholas H G Holford; Phylinda L S Chan; John G Nutt; Karl Kieburtz; Ira Shoulson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-04-20       Impact factor: 2.745

Review 5.  Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

Authors:  Amaal AlDakheel; Lorraine V Kalia; Anthony E Lang
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

6.  Acute L: -DOPA effect on hydroxyl radical- and DOPAC-levels in striatal microdialysates of parkinsonian rats.

Authors:  Przemysław Nowak; Rose Anna Kostrzewa; Dariusz Skaba; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2009-09-04       Impact factor: 3.911

Review 7.  Science, medicine, and the future: Parkinson's disease.

Authors:  A H Schapira
Journal:  BMJ       Date:  1999-01-30

Review 8.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

9.  The role of 3-O-methyldopa in the side effects of L-dopa.

Authors:  Eun-Sook Y Lee; Hongtao Chen; Jennifer King; Clivel Charlton
Journal:  Neurochem Res       Date:  2007-08-24       Impact factor: 3.996

10.  Altered transcription factor trafficking in oxidatively-stressed neuronal cells.

Authors:  Vivek P Patel; Donald B Defranco; Charleen T Chu
Journal:  Biochim Biophys Acta       Date:  2012-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.